Advances of the uricosuric drugs

YAO Guilin; WANG Haiyong; LU Tao

doi:10.11665/j.issn.1000-5048.20160417

Journal of China Pharmaceutical University > 2016 > 47(4): 491-496. > DOI: 10.11665/j.issn.1000-5048.20160417

YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417

Citation:

YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417

Citation:

YAO Guilin, WANG Haiyong, LU Tao. Advances of the uricosuric drugs[J]. Journal of China Pharmaceutical University, 2016, 47(4): 491-496. DOI: 10.11665/j.issn.1000-5048.20160417

PDF (1234 KB)

Advances of the uricosuric drugs

More Information

Graphical Abstract

Abstract

Abstract

Promoting uric acid excretion is an important approach for the treatment of gout and hyperuricemia. There are two main approaches included in the mechanism: one is inhibiting the function of renal tubular uric acid transporter to reduce the absorption of uric acid, and promoting excretion; the other is using uricase to catalyze the oxidation of uric acid to a more water-soluble allantoin that can also increase excretion. The mechanisms and progress of the uricosuric drugs are reviewed in this paper, providing reference for the further research and development.
- uricosuric,
- mechanisms,
- advances

FullText(HTML)

References (23)

References

[1]	Choi HK,Mount DB,Reginato AM,et al.Pathogenesis of gout [J].Ann Intern Med,2005,143(7):499-516.
[2]	Kang DH,Nakagawa T,Feng L,et al.A role for uric acid in the progression of renal disease [J].J Am Soc Nephrol,2002,13(12):2888-2897.
[3]	De Lau LM,Koudstaal PJ,Hofman A,et al.Serum uric acid levels and the risk of Parkinson disease [J].Ann Neurol,2005,58(5):797-800.
[4]	Rizwan AN,Burckhardt G.Organic anion transporters of the SLC22 family:biopharmaceutical,physiological,and pathological roles [J].Pharm Res,2007,24(3):450-470.
[5]	Anzai N,Jutabha P,Kanai Y,et al.Integrated physiology of proximal tubular organic anion transport [J].Curr Opin Nephrol Hypertens,2005,14(5):472-479.
[6]	Miyazaki H,Anzai N,Ekaratanawong S,et al.Modulation of renal apical organic anion transporter 4 function by two PDZ domain-containing proteins [J].J Am Soc Nephrol,2005,16(12):3498-3506.
[7]	Burns CM,Wortmann RL.Gout therapeutics:new drugs for an old disease [J].Lancet,2011,377(9760):165-177.
[8]	Matsuo H,Nakayama A,Sakiyama M,et al.ABCG2 dysfunction causes hyperuricemia due to both renal urate underexcretion and renal urate overload [J].Sci Rep,2014,4:3755.
[9]	Li S,Sanna S,Maschio A,et al.The GLUT9 gene is associated with serum uric acid levels in Sardinia and Chianti cohorts [J].PLoS Genet,2007,3(11):2156-2162.
[10]	Preitner F,Bonny O,Laverrière A,et al.Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy [J].Proc Natl Acad Sci U S A,2009,106(36):15501-15506.
[11]	Watanabe S,Kanellis J,Nakagawa T,et al.Reducing uric acid as a means to prevent cardiovascular and renal disease [J].Expert Opin Ther Pat,2002,12(2):193-199.
[12]	Fleischmann R,Kerr B,Yeh LT,et al.Pharmacodynamic,pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia [J].Rheumatology,2014,53(12):2167-2174.
[13]	Tan PK, Hyndman D, Liu S, et al. Lesinurad(RDEA594),a novel investigational uricosuric agent for hyperuricemia and gout,blocks transport of uric acid induced by hydrochlorothiazide[J].Ann Rheum Dis,2011,70(Suppl 3):187.
[14]	Miner JN, Tan P. RDEA3170, a novel, high affinity URAT1 inhibitor binds to a central domain within URAT1 [J].Ann Rheum Dis,2013,71(Suppl 3):446 [2015-07-14] .doi: 10.1136/annrheumdis-2012-eular.2846.
[15]	Ahn S,Horiba N,Ohtomo S,et al.The therapeutic efficacy of the novel uricosuric agent UR-1102 for hyperuricemia and gout[J].Ann Rheum Dis,2013,72(Suppl 3):A704 [2015-07-14] .doi: 10.1136/annrheumdis-2013-eular.2081.
[16]	Lavan BE,Mcwherter C,Choi YJ.Arhalofenate,a novel uricosuric agent,is an inhibitor of human URIC acid transporters [J].Ann Rheum Dis,2013,71(Suppl 3):450-451.
[17]	Steinberg A,Vince B,Choi YJ,et al.A Study to evaluate the pharmacodynamics,pharmacokinetics and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout [J].Ann Rheum Dis,2015,74(Suppl 2):543-544.
[18]	Noveck RJ,Wang ZY,Forathoefel A,et al.Levotofisopam has uricosuric activity and reduces serum urate levels in patients with gout [J].Arthitis Rheum,2012,64(Suppl 10):818.
[19]	Mandal A,Emerling D,Serafini T,et al.Tranilast inhibits urate transport mediated by URAT1 and GLUT9 [J].Arthritis Rheum,2010,62(Suppl 10):164.
[20]	Sundy JS,Kitt M,Griffith SG,et al.The combination of tranilast with allopurinol results in enhanced urate-lowering [J].Arthritis Rheum,2010,62(Suppl 10):S67-S68.
[21]	Warrell RP,Klukovits A,Barnes K,et al.Novel bifunctional inhibitors of xanthine oxidase and URAT1 induce profound hypouricemiain human subjects [J].Ann Rheum Dis,2014,73(Suppl 2):786.
[22]	Richette P,Briere C,Honene CV,et al.Rasburicase for tophaceous gout not treatable with allopurinol:an exploratory study [J].J Rheumatol,2007,34(10):2093-2098.
[23]	Sundy JS,Ganson NJ,Kelly SJ,et al.Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout [J].Arthritis Rheum,2007,56(3):1021-1028.

Cited By

Get Citation

PDF

XML

Article views (1005) PDF downloads (3989)

Turn off MathJax

Article Contents

Abstract

References

Advances of the uricosuric drugs

Abstract

References

Catalog

Export File

Citation

Format

Content